Review
Nature Reviews Cancer 8, 268-278 (April 2008) | doi:10.1038/nrc2351
There is a Corrigendum (1 May 2008) associated with this article.
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Hans Lilja1, David Ulmert2 & Andrew J. Vickers1 About the authors
Abstract
Testing for prostate-specific antigen (PSA) has profoundly affected the diagnosis and treatment of prostate cancer. PSA testing has enabled physicians to detect prostate tumours while they are still small, low-grade and localized. This very ability has, however, created controversy over whether we are now diagnosing and treating insignificant cancers. PSA testing has also transformed the monitoring of treatment response and detection of disease recurrence. Much current research is directed at establishing the most appropriate uses of PSA testing and at developing methods to improve on the conventional PSA test.
- View At a Glance
Author affiliations
- Departments of Surgery (Urology), Clinical Laboratories, Medicine (Genitourinary-Oncology), Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center New York, New York 10065, USA.
- Department of Laboratory Medicine, Lund University, University Hospital UMAS, 205 02 Malmö, Sweden.
Correspondence to: Hans Lilja1 Email: liljah@mskcc.org